Literature DB >> 12096344

The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.

Martin Lodén1, Maria Stighall, Niels Hilmer Nielsen, Göran Roos, Stefan O Emdin, Hanna Ostlund, Göran Landberg.   

Abstract

In an attempt to identify subtypes of breast cancer and pinpoint patterns of cell cycle regulatory defects associated with clinical behaviour, proliferation and other transformation associated events, a multitude of cell cycle regulatory proteins were analysed in a material of 113 primary breast cancers. Increased proliferation was observed in two different scenarios; (1) with high cyclin D1 and elevated retinoblastoma protein (pRb) phosphorylation, (cyclin D1(high) tumours) or (2) with high cyclin E protein but low cyclin D1 and lack of corresponding pRb phosphorylation (cyclin E(high) tumours) indicative of an interrupted pRb pathway. Characteristic for cyclin E(high) tumours were further defects in p53, p27 and bcl-2, while c-erbB2 overexpression and c-myc amplification was found in both cyclin D1(high) and E(high) tumours. Using transfected cell lines overexpressing cyclin E, cyclin E(high) and D1(high) tumours were mimicked and the cyclin D1(high) cell line normalized the cyclin E kinase activity by an induction and redirection of p21 and p27 to the cyclin E complex whereas cyclin E(high) cell lines obtained increased kinase activity without redirection of inhibitors. Based on differences in genetic aberrations as well as function of the pRb node we therefore propose a model in which cyclin D1(high) and cyclin E(high) tumours represent two alternative mechanisms to inactivate the pRb pathway and thereby achieve unrestrained growth in the tumorogenesis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096344     DOI: 10.1038/sj.onc.1205578

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.

Authors:  Agnieszka K Witkiewicz; Dayana B Rivadeneira; Adam Ertel; Jessica Kline; Terry Hyslop; Gordon F Schwartz; Paolo Fortina; Erik S Knudsen
Journal:  Am J Pathol       Date:  2011-07-12       Impact factor: 4.307

2.  Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features.

Authors:  Sophie Lehn; Nicholas P Tobin; Pontus Berglund; Kristina Nilsson; Andrew H Sims; Karin Jirström; Pirkko Härkönen; Rebecca Lamb; Göran Landberg
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

3.  Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Judith Schütte; Marijke N Boersma; Robert L Sutherland; Jason S Carroll; Elizabeth A Musgrove
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

4.  Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.

Authors:  Kathleen M Woods Ignatoski; Michele L Dziubinski; Cheryl Ammerman; Stephen P Ethier
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

5.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

Review 6.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

7.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Authors:  Patrick E Corsino; Bradley J Davis; Peter H Nørgaard; Nicole N Teoh Parker; Mary Law; William Dunn; Brian K Law
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.

Authors:  Donal J Brennan; Elton Rexhepaj; Sallyann L O'Brien; Elaine McSherry; Darran P O'Connor; Ailís Fagan; Aedín C Culhane; Desmond G Higgins; Karin Jirstrom; Robert C Millikan; Goran Landberg; Michael J Duffy; Stephen M Hewitt; William M Gallagher
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer.

Authors:  C Elizabeth Caldon; Elizabeth A Musgrove
Journal:  Cell Div       Date:  2010-01-17       Impact factor: 5.130

10.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.